



## **CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference**

March 30, 2017

BASEL, Switzerland and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Dr. Sam Kulkarni, Chief Business Officer of CRISPR Therapeutics, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5<sup>th</sup> at the Westin Grand Central Hotel, New York, NY.

Event: 16th Annual Needham Healthcare Conference

Date: Wednesday, April 5<sup>th</sup>

Time: 12:50-1:30 PM ET

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at [www.crisprtx.com](http://www.crisprtx.com).

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

### **MEDIA CONTACTS:**

Jennifer Paganelli  
WCG for CRISPR  
347-658-8290 [jpaganelli@wcgworld.com](mailto:jpaganelli@wcgworld.com)

### **INVESTOR CONTACT:**

Chris Brinzey  
Westwicke Partners for CRISPR  
339-970-2843 [chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



CRISPR Therapeutics AG